

MediPharm Labs forms multiple cannabis supply partnerships

04 September 2019 | News

Construction of New Melbourne-area Extraction Facility on Schedule



MediPharm Labs Corp., a global leader in specialized, research-driven cannabis extraction, distillation, purification and cannabinoid isolation, is pleased to announce that its subsidiary MediPharm Labs Australia Pty. Ltd. has entered a private label sales and manufacturing agreement with a Licensed Producer in Australia and taken other important steps to advance its early leadership in the Australian and Asia-Pacific extraction market.

Under the terms of the manufacturing agreement with the Licensed Producer, MediPharm Labs Australia will purchase dried flower from the Licensed Producer and sell high quality, private-label cannabis oil and manufactured products. The agreement has a 12-month term with options to extend.

MediPharm Labs Australia has also successfully negotiated multi-year supply agreements with three Australian Office of Drug Control (ODC) approved cultivators (including BBS Pharmaceuticals). This input supply will support the extraction and production of private label oil in Australia for local and international markets.

Construction of MediPharm Labs Australia's extraction and manufacturing facility in Wonthaggi, Victoria is progressing very well with completion on target before year-end 2019. The state-of-the-art facility will feature supercritical CO₂ extraction capacity to process up to 75,000 kg of dried cannabis annually as well secondary processing equipment for the manufacture of purified and high-concentrate cannabis distillate. Industrial-scale production will be supported by leading infrastructure designed with ISO standard-built cleanrooms and critical environments that accommodate global Good Manufacturing Practices ("GMP") workflow. Key customized equipment, including two primary extraction systems, have been ordered and shipped, with commissioning planned for November.

MediPharm Labs Australia received its cannabis manufacturing licence from the ODC under the Narcotics Drugs Act 1967 on May 21, 2019. Sales generation from the facility is expected to begin in the first half of 2020, subject to receipt of certain local authorizations and a certification from the Therapeutic Goods Association of Australia.